LGVN vs. STRO, RLMD, DTIL, INKT, NRXP, ICCC, CUE, GNTA, ALGS, and ANL
Should you be buying Longeveron stock or one of its competitors? The main competitors of Longeveron include Sutro Biopharma (STRO), Relmada Therapeutics (RLMD), Precision BioSciences (DTIL), MiNK Therapeutics (INKT), NRx Pharmaceuticals (NRXP), ImmuCell (ICCC), Cue Biopharma (CUE), Genenta Science (GNTA), Aligos Therapeutics (ALGS), and Adlai Nortye (ANL). These companies are all part of the "pharmaceutical products" industry.
Longeveron vs. Its Competitors
Longeveron (NASDAQ:LGVN) and Sutro Biopharma (NASDAQ:STRO) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, earnings, media sentiment, risk, profitability, analyst recommendations and dividends.
Sutro Biopharma has a net margin of -201.32% compared to Longeveron's net margin of -894.40%. Longeveron's return on equity of -95.91% beat Sutro Biopharma's return on equity.
Longeveron has higher earnings, but lower revenue than Sutro Biopharma. Sutro Biopharma is trading at a lower price-to-earnings ratio than Longeveron, indicating that it is currently the more affordable of the two stocks.
10.0% of Longeveron shares are owned by institutional investors. Comparatively, 97.0% of Sutro Biopharma shares are owned by institutional investors. 11.2% of Longeveron shares are owned by insiders. Comparatively, 3.6% of Sutro Biopharma shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Longeveron has a beta of 0.16, meaning that its share price is 84% less volatile than the S&P 500. Comparatively, Sutro Biopharma has a beta of 1.61, meaning that its share price is 61% more volatile than the S&P 500.
Longeveron currently has a consensus price target of $7.67, indicating a potential upside of 824.92%. Sutro Biopharma has a consensus price target of $4.47, indicating a potential upside of 285.06%. Given Longeveron's stronger consensus rating and higher probable upside, equities research analysts plainly believe Longeveron is more favorable than Sutro Biopharma.
In the previous week, Sutro Biopharma had 10 more articles in the media than Longeveron. MarketBeat recorded 11 mentions for Sutro Biopharma and 1 mentions for Longeveron. Sutro Biopharma's average media sentiment score of 1.44 beat Longeveron's score of 0.00 indicating that Sutro Biopharma is being referred to more favorably in the news media.
Summary
Longeveron and Sutro Biopharma tied by winning 8 of the 16 factors compared between the two stocks.
Get Longeveron News Delivered to You Automatically
Sign up to receive the latest news and ratings for LGVN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding LGVN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Longeveron Competitors List
Related Companies and Tools
This page (NASDAQ:LGVN) was last updated on 10/23/2025 by MarketBeat.com Staff
Free LGVN Stock Alerts